EE200200710A - Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks - Google Patents

Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks

Info

Publication number
EE200200710A
EE200200710A EEP200200710A EEP200200710A EE200200710A EE 200200710 A EE200200710 A EE 200200710A EE P200200710 A EEP200200710 A EE P200200710A EE P200200710 A EEP200200710 A EE P200200710A EE 200200710 A EE200200710 A EE 200200710A
Authority
EE
Estonia
Prior art keywords
treatment
cell growth
abnormal cell
substituted bicyclic
bicyclic derivatives
Prior art date
Application number
EEP200200710A
Other languages
English (en)
Inventor
Charles Kath John
Kumar Bhattacharya Samit
Morris Joel
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200710A publication Critical patent/EE200200710A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
EEP200200710A 2000-06-22 2001-06-14 Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks EE200200710A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22
PCT/IB2001/001046 WO2001098277A2 (en) 2000-06-22 2001-06-14 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
EE200200710A true EE200200710A (et) 2004-06-15

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200710A EE200200710A (et) 2000-06-22 2001-06-14 Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks

Country Status (43)

Country Link
US (2) US6890924B2 (et)
EP (1) EP1292591B1 (et)
JP (1) JP4044839B2 (et)
KR (1) KR100545537B1 (et)
CN (3) CN1330640C (et)
AP (1) AP2001002192A0 (et)
AR (1) AR032353A1 (et)
AT (1) ATE288431T1 (et)
AU (1) AU2001264159A1 (et)
BG (1) BG107269A (et)
BR (1) BR0111548A (et)
CA (1) CA2413424C (et)
CZ (1) CZ20023951A3 (et)
DE (1) DE60108754T2 (et)
DK (1) DK1292591T3 (et)
DZ (1) DZ3407A1 (et)
EA (1) EA005525B1 (et)
EC (1) ECSP024393A (et)
EE (1) EE200200710A (et)
ES (1) ES2236240T3 (et)
GE (1) GEP20063831B (et)
HK (1) HK1069576A1 (et)
HR (1) HRP20021005A2 (et)
HU (1) HUP0301120A2 (et)
IL (1) IL152985A0 (et)
IS (1) IS6616A (et)
MA (1) MA26914A1 (et)
MX (1) MXPA02012870A (et)
MY (1) MY127181A (et)
NO (1) NO20026166D0 (et)
NZ (1) NZ522568A (et)
OA (1) OA12291A (et)
PA (1) PA8520301A1 (et)
PE (1) PE20020257A1 (et)
PL (1) PL359557A1 (et)
PT (1) PT1292591E (et)
SK (1) SK17102002A3 (et)
SV (1) SV2002000504A (et)
TN (1) TNSN01091A1 (et)
UA (1) UA73990C2 (et)
WO (1) WO2001098277A2 (et)
YU (1) YU95102A (et)
ZA (1) ZA200210231B (et)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP2002526538A (ja) 1998-10-01 2002-08-20 アストラゼネカ アクチボラグ 化学化合物
EA005525B1 (ru) * 2000-06-22 2005-04-28 Пфайзер Продактс Инк. Замещенные бициклические производные для лечения аномального роста клеток
WO2002066445A1 (fr) * 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Derives de la quinazoline
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
CA2462149C (en) * 2001-11-30 2010-06-22 Pfizer Products Inc. Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
CN1602195A (zh) * 2001-12-12 2005-03-30 辉瑞产品公司 用于治疗异常细胞生长的喹唑啉衍生物
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
WO2004046101A2 (en) 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
CN1729001A (zh) * 2002-12-18 2006-02-01 辉瑞产品公司 用于治疗异常细胞生长的4－苯胺基喹唑啉衍生物
WO2004056802A1 (en) * 2002-12-19 2004-07-08 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
MXPA05008810A (es) * 2003-04-09 2005-10-18 Pfizer Prod Inc Procedimientos para preparar derivados biciclicos sustituidos.
JP2007501854A (ja) * 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
WO2005007184A2 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
PT1660090E (pt) 2003-08-14 2013-01-11 Array Biopharma Inc Análogos de quinazolina como inibidores de tirosina-cinases recetoras
JP2007502807A (ja) * 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
DK2210607T3 (da) * 2003-09-26 2011-12-12 Exelixis Inc N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft
MXPA06005024A (es) * 2003-11-06 2006-07-06 Pfizer Prod Inc Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
CN101010304A (zh) * 2004-09-01 2007-08-01 三菱制药株式会社 分子伴侣功能调节剂
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006114704A2 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
PT2447283E (pt) 2005-09-07 2015-10-08 Pfizer Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
US8648087B2 (en) 2005-11-15 2014-02-11 Array Biopharma, Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
AU2007251282A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
CN101535279B (zh) * 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2103620A1 (en) 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
NZ586582A (en) 2008-02-07 2012-07-27 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
EP2253633A4 (en) 2008-03-12 2012-02-29 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
WO2010083414A1 (en) 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2772194A1 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
ES2543151T3 (es) 2010-10-20 2015-08-17 Pfizer Inc Derivados de 2-piridina como moduladores del receptor Smoothened
AU2012311184A1 (en) 2011-09-22 2014-03-06 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
US20170050958A1 (en) 2014-04-30 2017-02-23 Pfizer Inc. Cycloalkyl-Linked Diheterocycle Derivatives
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
EP3424928A4 (en) 2016-03-01 2019-10-09 Shanghai Pharmaceuticals Holding Co., Ltd. HETEROCYCLIC NITROGEN COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CA3099776A1 (en) 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents
WO2023185793A1 (zh) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (et) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
KR100860295B1 (ko) 1998-10-08 2008-09-25 아스트라제네카 아베 퀴나졸린 유도체
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EA005525B1 (ru) * 2000-06-22 2005-04-28 Пфайзер Продактс Инк. Замещенные бициклические производные для лечения аномального роста клеток

Also Published As

Publication number Publication date
EP1292591A2 (en) 2003-03-19
CN1330640C (zh) 2007-08-08
BG107269A (bg) 2003-06-30
CZ20023951A3 (cs) 2004-01-14
IL152985A0 (en) 2003-06-24
NZ522568A (en) 2004-12-24
YU95102A (sh) 2005-11-28
JP2004501139A (ja) 2004-01-15
IS6616A (is) 2002-11-14
DE60108754T2 (de) 2005-06-23
MA26914A1 (fr) 2004-12-20
UA73990C2 (en) 2005-10-17
BR0111548A (pt) 2003-05-06
OA12291A (en) 2004-03-18
AR032353A1 (es) 2003-11-05
DE60108754D1 (de) 2005-03-10
WO2001098277A2 (en) 2001-12-27
NO20026166L (no) 2002-12-20
JP4044839B2 (ja) 2008-02-06
KR20030016303A (ko) 2003-02-26
MY127181A (en) 2006-11-30
EP1292591B1 (en) 2005-02-02
US7332493B2 (en) 2008-02-19
ATE288431T1 (de) 2005-02-15
ZA200210231B (en) 2004-02-12
PT1292591E (pt) 2005-06-30
PA8520301A1 (es) 2003-06-30
KR100545537B1 (ko) 2006-01-25
US20020169165A1 (en) 2002-11-14
US20050159435A1 (en) 2005-07-21
US6890924B2 (en) 2005-05-10
CN1437594A (zh) 2003-08-20
SK17102002A3 (sk) 2004-04-06
TNSN01091A1 (fr) 2005-11-10
WO2001098277A3 (en) 2002-06-13
CN1576275A (zh) 2005-02-09
GEP20063831B (en) 2006-05-25
PE20020257A1 (es) 2002-04-08
ECSP024393A (es) 2003-02-06
HRP20021005A2 (en) 2004-02-29
NO20026166D0 (no) 2002-12-20
DK1292591T3 (da) 2005-05-30
EA005525B1 (ru) 2005-04-28
EA200201277A1 (ru) 2003-06-26
HK1069576A1 (en) 2005-05-27
PL359557A1 (en) 2004-08-23
HUP0301120A2 (hu) 2003-08-28
SV2002000504A (es) 2002-10-24
CA2413424C (en) 2007-10-02
DZ3407A1 (et) 2001-12-27
AU2001264159A1 (en) 2002-01-02
MXPA02012870A (es) 2003-05-14
CA2413424A1 (en) 2001-12-27
ES2236240T3 (es) 2005-07-16
CN101348467A (zh) 2009-01-21
AP2001002192A0 (en) 2002-12-21

Similar Documents

Publication Publication Date Title
EE200200710A (et) Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks
ATE458731T1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
IL161908A0 (en) Quinazoline derivatives for the treatment of abnormal cell growth
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20053483D0 (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
IL160971A0 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20042542L (no) Anvendelse av ascomycin for behandling av blefarit
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
AU2002338794A1 (en) Use of mannosamine derivatives for the stimulation of neurite growth
NO996166L (no) FremgangsmÕte for behandling av avluter
FI20021478A0 (fi) Menetelmä kuitupuun käsittelemiseksi
ITMI20000147A0 (it) Procedimeto per il trattamento di fanghi